Harbour BioMed, a global biopharmaceutical company focused on advancing innovative antibody-based therapies in immunology and immune-oncology, has announced the online publication of results from the first-in-human Phase I clinical trial …
A decade ago, the evolution of immuno-oncology altered the therapeutic landscape for patients with a variety of cancers. Although individual immunotherapies have improved patient outcomes, the addition of rational combinations …
